Omega-3 fatty acid eicosapentaenoic acid. A new treatment for psychiatric and neurodegenerative diseases: A review of clinical investigations

Expert Opinion on Investigational Drugs

Volumn 16, Issue 10, 2007, Pages 1627-1638

  Song, Cai ^a   Zhao, Shannon ^b  

^a UNIVERSITY OF PRINCE EDWARD ISLAND   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; Depression; Eicosapentaenoic acid; Huntington's disease; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOCOSAHEXAENOIC ACID; FISH OIL; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; INTERLEUKIN 1BETA; LAX 101; LITHIUM CARBONATE; MIRAXION; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID; ANTIINFLAMMATORY AGENT; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BIPOLAR DEPRESSION; BREATHING DISORDER; CLINICAL TRIAL; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EVIDENCE BASED PRACTICE; FATTY ACID BLOOD LEVEL; FOOD INTAKE; GASTROINTESTINAL DISEASE; HUMAN; HUNTINGTON CHOREA; LOW DRUG DOSE; MAJOR DEPRESSION; MENTAL DISEASE; MONOTHERAPY; MOTOR PERFORMANCE; NEUROTRANSMITTER RELEASE; NONHUMAN; PSYCHOLOGICAL RATING SCALE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH DISEASE; SYNAPTIC TRANSMISSION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ANIMAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS; EICOSAPENTAENOIC ACID; HUMANS; MENTAL DISORDERS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS;

EID: 35248877220     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.10.1627     Document Type: Review

References (57)

1. HORROBIN FD, BENNETT CN: Phospholipid metabolism and the pathophysiology of psychiatric and neurological disorders. In: Phospholipid Spectrum Disorder in Psychiatry and Neurology (2nd Edition). Peet M, Glen I, Horrobin DF (Eds), Marius Press, Lancashire, UK (2003):3-47.
2. YEHUDA S, RABINOVITZ S, CARASSO RL, MOSTOFSKY DI: The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol Aging (2002) 23:843-853.
3. MAZZA M, POMPONI M, JANIRI L, BRIA P, MAZZA S: Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: an overview. Prog. Neuropsycho. Pharmacol. Biol. Psychiatry (2007) 31(1):12-26.
4. ANDREINI I, GETULI C, PACELLI V et al.: Function of the hypothalamus-pituitary-adrenal axis and humoral immune mechanisms during experimental allergic encephalomyelitis in SJL/J mice. Neuroimmunomodulation (2002) 10:9-16.
5. PAVLIDES C, NIVON LG, MCEWEN BS: Effects of chronic stress on hippocampal long-term potentiation. Hippocampus (2002) 12:245-257.
6. ELGH E, LINDQVIST ASTOT A, FAGERLUND M et al.: Cognitive dysfunction, hippocampal atrophy and glucocorticoid feedback in Alzheimer's disease. Biol. Psychiatry (2006) 59:155-161.
7. JAMES MJ, GIBSON RA, CLELAND LG: Dietary polyunsaturated fatty acids and inflammatory mediator production. Am. J. Clin. Nutr. (2000) 71(1 Suppl.):S343-S348.
8. HUANG TL, ZANDI PP, TUCKER KL et al.: Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology (2005) 65:1409-1414.
9. DE LAU LM, BORNEBROEK M, WITTEMAN JC et al.: Dietary fatty acids and the risk of Parkinson's disease: the Rotterdam study. Neurology (2005) 64:2040-2045.
10. MAES M, CHRISTOPHE A, DELANGHE J, ALTAMURA C, NEELS H, MELTZER HY: Lowered omega 3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. (1999) 85(3):275-291.
11. HIBBELN JR: Fish consumption and major depression. Lancet (1998) 351(9110):1213.
12. NEMETS B, STAHL Z, BELMAKER RH: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry (2002) 159(3):477-479.
13. SU KP, HUANG SY, CHIU CC, SHEN WW: Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur. Aeuropsychopharmacol, (2003) 13(4):267-271.
14. NOAGHIUL S, HIBBELN JR: Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am. J. Psychiatry (2003) 160(12):2222-2227.
15. COTT J, HIBBELN JR. Lack of seasonal mood change in Icelanders. Am. J. Psychiatry (2001) 158(2):328.
16. HUAN M, HAMAZAKI K, SUN Y et al.: Suicide attempt and n-3 fatty acid levels in red blood cells: a case control study in China. Biol. Pychiatry (2004) 56(7):490-496.
17. CONQUER JA, TIERNEY MC, ZECEVIC J, BETTGER WJ, FISHER RH: Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids (2000) 35(12):1305-1312.
18. REDDY RD, KESHAVAN MS, YAO JK: Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr. Bull. (2004) 30(4):901-911.
19. VADDADI KS, COURTNEY P, GILLEARD CJ, MANKU MS, HORROBIN DF: A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res. (1989) 27:313-323.
20. LYNCH AM, LOANE DJ, MINOGUE AM et al.: Eicosapentaenoic acid confers neuroprotection in the amyloid-β challenged aged hippocampus. Neurobiol. Aging (2006) 28(6):845-855.
21. SONG C, LI X, LEONARD BE, HORROBIN DF: Effects of dietary n-3 or n-6 fatty acids on interleukin-1β-induced anxiety, stress, and inflammatory responses in rats. J. Lipid Res. (2003) 44(10):1984-1991.
22. SONG C, HORROBIN D: Omega-3 fatty acid ethyl-eicosapentaenoate, but not soybean oil, attenuates memory impairment induced by central IL-1β administration. J. Lipid Res. (2004) 45(6):1112-1121.
23. SONG C, PHILLIPS AG, LEONARD BE, HORROBIN DF: Ethyl-eicosapentaenoic acid ingestion prevents corticosterone-mediated memory impairment induced by central administration of interleukin-1β in rats. Mol. Psychiatry (2004) 9(6):630-638.
24. SONG C: EPA alone or combination with GLA modulate gene expression related to stress and inflammation in a rodent model of depression. Brain Behav. Immun. (2005) 14:77-140.
25. PEET M, BRIND J, RAMCHAND CN, SHAH S, VANKAR GK: Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr. Res. (2001) 49(3):243-251.
26. MARANGELL LB, MARTINEZ JM, ZBOYAN HA et al.: A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am. J. Psychiatry (2003) 160(5):996-998.
27. XUE H, WAN M, SONG D, LI Y, LI J: Eicosapentaenoic acid and docosahexaenoic acid modulate mitogen-activated protein kinase activity in endothelium. Vascul. Pharmacol. (2006) 44(6):434-439.
28. STOREY A, MCARDLE F, FRIEDMANN PS, JACKSON MJ, RHODES LE: Eicosapentaenoic acid and docosahexaenoic acid reduce UVB- and TNF-α-induced IL-8 secretion in keratinocytes and UVB-induced IL-8 in fibroblasts. J. Invest. Dermatol. (2005) 124(1):248-255.
29. KHALFOUN B, THIBAULT F, WATIER H, BARDOS P, LEBRANCHU Y. Docosahexacnoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6. Adv. Exp. Med. Biol. (1997) 400B:589-597.
30. PEET M, HORROBIN DF: A dose-ranging study of the effects of ethyl-eicopentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry (2002) 59(10):913-919.
31. PURI BK, COUNSELL SJ, HAMILTON G et al.: Eicosapentaenoic acid in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover. Int. J. Clin. Pract. (2001) 55(8):560-563.
32. OSHER Y, BERSUDSKY Y, BELMAKER RH: Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J. Clin. Pychiatry (2005) 66(6):726-729.
33. KINRYS G: Hypomania associated with omega-3 fatty acids [letter]. Gen. Psychiatry (2002) 57(7):715-716.
34. KECK PE, MINTZ J, MCELROY SL et al.: Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol, Psychiatry (2006) 60(9):1020-1022.
35. FRANGOU S, LEWIS M: The Maudsley bipolar project: a double-blind, randomised, placebo-controlled study of ethyl-EPA as an adjunct treatment of depression in bipolar disorder. Bipolar Disord. (2002) 4:123 (Abstract).
36. FRANGOU S, LEWIS M, MCCRONE P: Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br. J. Psychiatry (2006) 188:46-50.
37. FRANGOU S, LEWIS M, WOLLARD J et al.: Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentaenoic acid treatment in patients with bipolar disorder. J. Pychopharmacol. (2007) 21(4):435-439.
38. RICHARDSON AJ, EASTON T, PURI BK: Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid. Eur. Neuropsychopharmacol. (2000) 10(3):189-193.
39. PURI BK, RICHARDSON AJ, HORROBIN DF et al.: Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes. Int. J. Clin. Pract. (2000) 54(1):57-63.
40. YAO JK, MAGAN S, SONEL AF et al.: Effects of omega-3 fatty acid in platelet serotonin responsiviry in patients with schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids (2004) 71(3):171-176.
41. EMSLEY R, MYBURGH C, OOSTHUIZEN P, VAN RENSBURG SJ: Randomized, placebo-controlled study of ethyl-eicosapemaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry (2002) 159(9):L1596-L1598.
42. EMSLEY R, NIEHAUS DJ, KOEN L et al.: The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr. Res. (2006) 84(1):112-120.
43. FENTON WS, DICKERSON F, BORONOW J, HIBBEIN JR, KNABLE M: A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapcntaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Pychiatry (2001) 158(12):2071-2074.
44. PEET M, HORROBIN DF; E-E MULTICENTRE STUDY GROUP: A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Pychiatr. Res. (2002) 36(1):7-18.
45. HORROBIN DF, JENKINS K BENNETT CN, CHRISTIE WW: Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding. Prostaglandins Leukot Essent Fatty Acids (2002) 66(1):83-90.
46. BOSTON PF, BENNETT A, HORROBIN DF, BENNETT CN: Ethyl-EPA in Alzheimees disease - a pilot study. Prostaglandins Leukot. Essent. Fatty Acids (2004) 71(5):341-346.
47. FREUND-LEVI Y, ERIKSDOTTER-JONHAGEN M, CEDERHOLM T et al.: Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer's disease: omega AD study: a randomized double-blind trial. Arch. Neurol. (2006) 63(10):1402-1408.
48. VADDADI K: Essential fatty acids in the treatment of Huntington's disease. In: Phospholpid Spectrum Disorder, (2nd Edition). Peet M, Iain G, Horrobin DF (Eds), Marius Press, UK (2003):565-574.
49. PURI BK, LEAVITT BR, HAYDEN MR et al.: Ethyl-EPA in Huntington's disease: a double-blind, randomized, placebo-controlled trial. Neurology (2005) 65(2):286-292.
50. PURI BK BYDDER GM, COUNSELL SJ et al.: MRI and neuropsychological improvement in Huntington's disease following ethyl-EPA treatment. Neuroreport (2002) 13(1):123-126.
51. DE LAU LM, BORNEBROEK M, WITTEMAN JCM, HOFMAN A, KOUDSTAAL PJ, BRETELER MMB: Dietary fatty acids and the risk of Parkinson's disease. Neurology (2005) 64(12):2040-2045.
52. DAS UN: Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how? Prostaglandins Leukot. Essent. Fatty Acids (2000) 63(6):351-362.
53. SCHMIDT EB, DYERBERG J: n-3 fatty acids and leucocytes. J. Intern. Med. Suppl. (1989) 731:151-158.
54. BERGER GE, SMESNY S, AMMINGER GP: Bioactive lipids in schizophrenia. Int. Rev. Psychiatry (2006) 18(2):85-98.
55. STOLL AL, SEVERUS WE, FREEMAN MP et al.: Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry (1999) 56(5):407-412.
56. SAMPALIS F, BUNEA R, PELLAND MF, KOWALSKI O, DUGUET N, DUPUIS S: Evaluation of the effects of Neptune krill oil on the management of premenstrual syndrome and dysmenorrhea. Altern. Med. Rev. (2003) 8(2):171-179.
57. ZANARINI MC, FRANKENBURG FR: Omega-3 fatty acid treatment of women with borderline personality disorder. a double-blind, placebo-controlled pilot study. Am. J. Psychiatry (2003) 160(1):167-169.